Last Price
43.36
Today's Change
+2.009 (4.86%)
Day's Change
42.04 - 43.57
Trading Volume
267,387
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Dominick C. Colangelo Esq. Mr. Dominick C. Colangelo Esq.
Full Time Employees: 314 314
IPO Date: 1997-02-04 1997-02-04
CIK: 0000887359 0000887359
ISIN: US92346J1088 US92346J1088
CUSIP: 92346J108 92346J108
Beta: 1.67 1.67
Last Dividend: 0.00 0.00
Dcf Diff: 39.38 39.38
Dcf: 3.98 3.98
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.